Characteristics of the 520 patients with pancreatic ductal adenocarcinoma
| Characteristic | Cases, n (%) | Ki-67 expression level | χ2/Z | P | |
|---|---|---|---|---|---|
| Low-expression group, n (%) | High-expression group, n (%) | ||||
| Gender | 2.082 | 0.149 | |||
| Male | 295 (56.7) | 153 (53.9) | 142 (60.2) | ||
| Female | 225 (43.3) | 131 (46.1) | 94 (39.8) | ||
| Age (years) | 0.141 | 0.707 | |||
| < 70 | 444 (85.4) | 244 (85.9) | 200 (84.7) | ||
| ≥ 70 | 76 (14.6) | 40 (14.1) | 36 (15.3) | ||
| Preoperative serum CA19-9 (U/mL) | −1.744 | 0.081 | |||
| < 200 | 284 (54.6) | 165 (50.4) | 119 (50.4) | ||
| 200–1000 | 157 (30.2) | 80 (32.6) | 77 (32.6) | ||
| > 1000 | 79 (15.2) | 39 (13.7) | 40 (16.9) | ||
| Preoperative serum CEA (ng/mL) | 4.293 | 0.038 | |||
| ≤ 5 | 361 (69.4) | 208 (73.2) | 153 (64.8) | ||
| > 5 | 159 (30.6) | 76 (26.8) | 83 (35.2) | ||
| Tumor location | 3.418 | 0.064 | |||
| Head | 350 (67.3) | 201 (70.8) | 149 (63.1) | ||
| Body and tail | 170 (32.7) | 83 (29.2) | 87 (36.9) | ||
| Type of pancreatectomy | 3.059 | 0.080 | |||
| PD | 351 (67.5) | 201 (70.8) | 150 (63.6) | ||
| DP | 169 (32.5) | 83 (29.2) | 86 (36.4) | ||
| Histopathologic differentiation | 1.014 | 0.314 | |||
| Well and moderate | 208 (40.0) | 108 (38.0) | 100 (42.4) | ||
| Poor | 312 (60.0) | 176 (62.0) | 136 (57.6) | ||
| T stage | 3.285 | 0.350 | |||
| T1 | 79 (15.2) | 48 (16.9) | 31 (13.1) | ||
| T2 | 278 (53.5) | 155 (54.6) | 123 (52.1) | ||
| T3 | 149 (28.7) | 73 (25.7) | 76 (32.2) | ||
| T4 | 14 (2.7) | 8 (2.8) | 6 (2.5) | ||
| N stage | 2.979 | 0.225 | |||
| N0 | 244 (46.9) | 143 (50.4) | 101 (42.8) | ||
| N1 | 124 (23.8) | 64 (22.5) | 60 (25.4) | ||
| N2 | 152 (29.2) | 77 (27.1) | 75 (31.8) | ||
| TNM stage | 4.489 | 0.106 | |||
| I | 168 (32.3) | 103 (36.3) | 65 (27.5) | ||
| II | 191 (36.7) | 98 (34.5) | 93 (39.4) | ||
| III | 161 (31.0) | 83 (29.2) | 78 (33.1) | ||
| Perineural invasion | 0.559 | 0.455 | |||
| Absent | 183 (35.2) | 104 (36.6) | 79 (33.5) | ||
| Present | 337 (64.8) | 180 (63.4) | 157 (66.5) | ||
| Lymphovascular invasion | 3.895 | 0.048 | |||
| Absent | 381 (73.3) | 218 (76.8) | 163 (69.1) | ||
| Present | 139 (26.7) | 66 (23.2) | 73 (30.9) | ||
| Postoperative complications | 0.590 | 0.442 | |||
| Present | 134 (25.8) | 77 (27.1) | 57 (24.2) | ||
| Absent | 386 (74.2) | 207 (72.9) | 179 (75.8) | ||
| Postoperative adjuvant chemotherapy regimens | 4.439 | 0.350 | |||
| None | 255 (49.0) | 131 (46.1) | 124 (52.5) | ||
| mFOLFIRINOX | 66 (12.7) | 41 (14.4) | 25 (10.6) | ||
| GS/GX | 109 (21.0) | 58 (20.4) | 51 (21.6) | ||
| S-1 | 45 (8.7) | 25 (8.8) | 20 (8.5) | ||
| Gemcitabine | 45 (8.7) | 29 (10.2) | 16 (6.8) | ||
CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; DP, distal pancreatectomy; PD, pancreaticoduodenectomy.